ADB-BINACA (also known as ADMB-BZINACA using EMCDDA naming standards) is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products. It was originally developed by Pfizer as a potential analgesic, and is a potent agonist of the CB<sub>1</sub> receptor with a binding affinity (K<sub>i</sub>) of 0.33 nM and an EC<sub>50</sub> of 14.7 nM.
The analogue with a 1-butyl substitution on the indazole ring rather than 1-benzyl has also been sold as a designer drug under the name ADB-BINACA, but is now more commonly referred to as ADB-BUTINACA to avoid confusion with the benzyl compound. It is a similarly potent CB<sub>1</sub> agonist, with a binding affinity of 0.29nM for CB1 and 0.91nM for CB2, and an EC<sub>50</sub> of 6.36 nM for CB1.